Randomized, Placebo-controlled, Dose-escalation, Double-blind Study of Dasiglucagon Effects on QTc in Healthy Volunteers

First published in Current Therapeutic Research in 2022.
Current Therapeutic Research, Volume 96, 2022, Article 100668 doi.org/10.1016/j.curtheres.2022.100668

Authors: Ramin Tehranchi MD, PhD, MBA, Anita E.Melgaard MSc, Friedeborg Seitz MD, Anders Valeur PhD, Stine Just Maarbjerg PhDS

Download full article as Pdf file:

Pdf File

REACHING OUT IS EASY AND FAST – LET’S TALK

Prof. Dr. Thomas Forst

Chairman of the Executive Board

LET’S TALK SCIENCE

+49 621 150 45 – 0

Martin Mulder

Senior Vice President Corporate & Business Development

LET’S TALK BUSINESS

+49 621 150 45 – 0

Randomized, Placebo-controlled, Dose-escalation, Double-blind Study of Dasiglucagon Effects on QTc in Healthy Volunteers

Read more

REACHING OUT IS EASY AND FAST – LET’S TALK

You May Also Like

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies.

(Bersacapavir) In Participants With Moderate Hepatic Impairment.